Compare Revvity Inc (RVTY) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M). The key difference: Revvity Inc is far larger — about 24.3× YieldMax TSLA Option Income Strategy ETF's market cap, and Revvity Inc pays a 0.18% dividend while YieldMax TSLA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| RVTY | TSLY | |
|---|---|---|
Market Cap | $16.98B | $697.51M |
Volume | 1,456,900 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $157.36 | $43.35 |
52-Week Low | $82.26 | $20.49 |
Typical Hold Time | 12 Days | 43 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
TSLY trades at $22.27, down 1.46% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF generates high income through weekly dividends, averaging around $0.21-$0.26 per share recently. Recent news highlights consistent distribution announcements but also notes underperformance versus Tesla's equity rally due to its option income strategy structure.
The outlook is mixed: high yield appeals to income seekers, but the strategy caps upside during Tesla rallies. Key risks include dependence on Tesla's volatility and potential NAV erosion. Investors should weigh income generation against limited capital appreciation potential in a bullish Tesla market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
